SecProbe.io

CORRESP
 1
 filename1.htm

 April
1, 2025

 VIA
EDGAR

 U.S.
Securities and Exchange Commission

 Division
of Corporation Finance

 Office
of Technology

 100
F Street, N.E.

 Washington,
D.C. 20549

 Attention:
Anastasia Kaluzienski and Robert Littlepage

 Re: Polomar
 Health Services, Inc.
 Amendment
 No. 1 to the Form 10-Q for the Period Ended September 30, 2024

 File
 No. 000-56555

 Ladies
and Gentlemen:

 On
behalf of our client, Polomar Health Services, Inc. (the "Company"), we are submitting this letter in response to the written
comments of the staff (the "Staff") of the Securities and Exchange Commission (the "Commission") contained in
the Staff's letter dated March 17, 2025 (the "Comment Letter"), with respect to the Company's Amendment No. 1
to the Form 10-Q for the Period Ended September 30, 2024, filed on March 7, 2025 (the "Form 10-Q/A").

 The
Staff's comments call for the explanation of, or supplemental information as to, various matters relating to disclosures provided
in the Form 10-Q/A. Responses to these comments have been provided by the Company to us and are set forth in this letter.

 The
Company's responses are set forth below, with the heading and numbered item of this letter corresponding to the heading and numbered
item contained in the Comment Letter. To assist the Staff's review, the comment from the Comment Letter is restated in bold italics
prior to the Company's response.

 Amendment
No. 1 to the Form 10-Q for the Period Ended September 30, 2024

 License
Agreement Valuation, page F-7

 1. We
 note your response to prior comment 2 in which you indicate that you have eliminated the
 section regarding "Merger Valuation" and adjusted the value of intellectual property
 and other intangible assets in your amended Form 10-Q for the Period Ended September 30,
 2024. We also note that in your Form 10-Q for the Period Ended September 30, 2024, filed
 on November 19, 2024, you disclosed that as of the date of the filing the license agreement
 had no value, and you did not record any other intangible assets on your balance sheet. In
 light of prior reporting, please tell your basis, with reference to accounting literature,
 for recording intellectual property and other intangible assets as of September 30, 2024.
 In this regard, please provide us a detailed analysis to show how you valued intellectual
 property and other intangible assets.

 We
respectfully advise the Staff that, utilizing the guidance afforded under ASC 820, Fair Value Measurement, the Company
applied an income approach valuation to establish the fair market value of the intellectual property acquired in the reverse merger,
specifically, the License Agreement. Please see Net Present Value ("NPV") calculation at September 30, 2024 of the
license agreement based upon pro-forma income assumptions, attached as Exhibit A to this Response Letter. The Company's
Quarterly Report on Form 10-Q for the period ended September 30, 2024, filed on November 19, 2024, inadvertently aggregated intellectual
property and other intangible assets on the balance sheet as "Intellectual property", which was bifurcated as separate
entries on the balance sheet in the Form 10-Q/A; further the description of the value of the license agreement is correct in that
no expenses were incurred and no revenue was recognized at September 30, 2024, but the valuation of the license at -0- is an error which
was corrected on the balance sheet in the Form 10-Q/A.

 Other
intangible assets consist of the domain names SlimRx.com, Polomeds.com, Polomarsp.com, Polomarhs.com, and non-proprietary medication
formulations. The Company incurred expenses in acquiring the domain names, including additional obligations in the development of the
websites and ongoing annual maintenance of those websites. Utilizing a cost approach valuation method pursuant to ASC 820, the Company
determined the Fair Value of other intangible assets to be $250,000 at September 30, 2024. Please see attached ten-year
pro-forma cost analysis associated with the domain names, attached as Exhibit B to this Response Letter.

 *
* * * *

 We
thank you for your prompt attention to this letter and look forward to hearing from you at your earliest convenience. Please do not hesitate
to contact the undersigned at (516) 663-6580 with any questions or further comments you have regarding this filing or if you wish to
discuss the above responses.

 Very truly yours,

 /s/ Stephen E. Fox

 STEPHEN E. FOX

 For the Firm

 cc: Terrence
 M. Tierney, President and CFO, Polomar Health Services, Inc.

 EXHIBIT
A

 NET
PRESENT VALUE CALCULATION

 Calculation of Present Value of Licensed
IP

 Useful Length of License = 5 years

 License is non-exclusive and patents have not yet issued.

 Estimated Sales

 Drug
 Jan-25
 Feb-25
 Mar-25
 Apr-25
 May-25
 Jun-25
 Jul-25
 Aug-25
 Sep-25
 Oct-25
 Nov-25
 Dec-25
 2025
 COGS
 Royalty
 Net Revenue

 Inhalable Sildenafil

 $ 40,000
 $ 50,000
 $ 62,500
 $ 152,500
 $ 61,000.00
 $ 22,875.00
 $ 68,625.00

 Inhalable Sumatriptan

 $ 5,000
 $ 6,250
 $ 7,813
 $ 19,063
 $ 7,625.00
 $ 2,859.38
 $ 8,578.13

 $ 45,000
 $ 56,250
 $ 70,313
 $ 171,563
 $ 68,625.00
 $ 25,734.38
 $ 77,203.13

 Net Present Value @ 09/24
 $ 58,802.97

 Jan-26
 Feb-26
 Mar-26
 Apr-26
 May-26
 Jun-26
 Jul-26
 Aug-26
 Sep-26
 Oct-26
 Nov-26
 Dec-26
 2026

 Inhalable
 Sildenafil
 $ 75,000
 $ 90,000
 $ 108,000
 $ 129,600
 $ 155,520
 $ 186,624
 $ 223,949
 $ 268,739
 $ 322,486
 $ 386,984
 $ 464,380
 $ 557,256
 $ 2,968,538
 $ 1,187,415.07
 $ 445,280.65
 $ 1,335,841.95

 Inhalable
 Sumatriptan
 $ 9,375
 $ 11,250
 $ 13,500
 $ 16,200
 $ 19,440
 $ 23,328
 $ 27,994
 $ 33,592
 $ 40,311
 $ 48,373
 $ 58,048
 $ 69,657
 $ 371,067
 $ 148,426.88
 $ 55,660.08
 $ 166,980.24

 Metformin
 Gummy
 $ 10,000
 $ 11,000
 $ 12,100
 $ 13,310
 $ 14,641
 $ 16,105
 $ 17,716
 $ 19,487
 $ 21,436
 $ 23,579
 $ 25,937
 $ 28,531
 $ 42,797
 $ 17,118.70
 $ 4,279.68
 $ 21,398.38

 $ 94,375
 $ 112,250
 $ 133,600
 $ 159,110
 $ 189,601
 $ 226,057
 $ 269,658
 $ 321,818
 $ 384,233
 $ 458,936
 $ 548,365
 $ 655,444
 $ 3,382,402
 $ 1,352,960.65
 $ 505,220.41
 $ 1,524,220.57

 Net
 Present Value @ 09/24
 $ 927,688.54

 Jan-27
 Feb-27
 Mar-27
 Apr-27
 May-27
 Jun-27
 Jul-27
 Aug-27
 Sep-27
 Oct-28
 Nov-27
 Dec-27
 2027

 Inhalable
 Sildenafil
 $ 585,119
 $ 614,375
 $ 645,094
 $ 677,348
 $ 711,216
 $ 746,777
 $ 765,446
 $ 784,582
 $ 804,197
 $ 824,302
 $ 844,909
 $ 866,032
 $ 8,869,397
 $ 3,547,758.95
 $ 1,330,409.61
 $ 3,991,228.82

 Inhalable
 Sumatriptan
 $ 76,623
 $ 84,285
 $ 92,714
 $ 101,985
 $ 112,183
 $ 123,402
 $ 135,742
 $ 149,316
 $ 164,248
 $ 180,672
 $ 198,740
 $ 218,614
 $ 1,638,522
 $ 655,408.95
 $ 245,778.36
 $ 737,335.07

 Metformin
 Gummy
 $ 31,384
 $ 34,523
 $ 37,975
 $ 39,874
 $ 41,867
 $ 43,961
 $ 46,159
 $ 48,467
 $ 50,890
 $ 52,162
 $ 53,466
 $ 54,803
 $ 82,205
 $ 32,881.85
 $ 8,220.46
 $ 41,102.31

 $ 693,126
 $ 733,183
 $ 775,782
 $ 819,207
 $ 865,267
 $ 914,139
 $ 947,347
 $ 982,365
 $ 1,019,335
 $ 1,057,137
 $ 1,097,115
 $ 1,139,449
 $ 10,590,124
 $ 4,236,049.75
 $ 1,584,408.43
 $ 4,769,666.20

 Net
 Present Value @ 09/24
 $ 2,412,997.95

 Jan-28
 Feb-28
 Mar-28
 Apr-28
 May-28
 Jun-28
 Jul-28
 Aug-28
 Sep-28
 Oct-28
 Nov-28
 Dec-28
 2027

 Inhalable
 Sildenafil
 $ 909,334
 $ 920,700
 $ 932,209
 $ 943,862
 $ 955,660
 $ 967,606
 $ 979,701
 $ 991,947
 $ 1,004,346
 $ 1,016,901
 $ 1,029,612
 $ 1,042,482
 $ 11,694,359
 $ 4,677,743.68
 $ 1,754,153.88
 $ 5,262,461.64

 Inhalable
 Sumatriptan
 $ 229,544
 $ 241,022
 $ 253,073
 $ 265,726
 $ 279,013
 $ 292,963
 $ 307,611
 $ 322,992
 $ 339,141
 $ 356,099
 $ 373,903
 $ 392,599
 $ 3,653,686
 $ 1,461,474.24
 $ 548,052.84
 $ 1,644,158.52

 Metformin
 Gummy
 $ 57,543
 $ 60,420
 $ 63,441
 $ 66,613
 $ 69,944
 $ 73,441
 $ 77,113
 $ 80,969
 $ 85,018
 $ 89,268
 $ 93,732
 $ 98,418
 $ 147,628
 $ 59,051.08
 $ 14,762.77
 $ 73,813.85

 $ 1,196,421
 $ 1,222,142
 $ 1,248,723
 $ 1,276,201
 $ 1,304,617
 $ 1,334,010
 $ 1,364,426
 $ 1,395,908
 $ 1,428,505
 $ 1,462,268
 $ 1,497,247
 $ 1,533,499
 $ 15,495,672
 $ 6,198,269.00
 $ 2,316,969.49
 $ 6,980,434.00

 Net
 Present Value @ 09/24
 $ 3,035,014.29

 Jan-29
 Feb-29
 Mar-29
 Apr-29
 May-29
 Jun-29
 Jul-29
 Aug-29
 Sep-29
 Oct-29
 Nov-29
 Dec-29
 2027

 Inhalable
 Sildenafil
 $ 1,055,513
 $ 1,068,707
 $ 1,082,066
 $ 1,095,592
 $ 1,109,287
 $ 1,123,153
 $ 1,137,192
 $ 1,151,407
 $ 1,165,800
 $ 1,180,372
 $ 1,195,127
 $ 1,210,066
 $ 13,574,280
 $ 5,429,712.11
 $ 2,036,142.04
 $ 6,108,426.13

 Inhalable
 Sumatriptan
 $ 412,229
 $ 422,534
 $ 433,098
 $ 443,925
 $ 455,023
 $ 466,399
 $ 478,059
 $ 490,010
 $ 502,260
 $ 514,817
 $ 527,687
 $ 540,880
 $ 5,686,921
 $ 2,274,768.46
 $ 853,038.17
 $ 2,559,114.51

 Metformin
 Gummy
 $ 103,339
 $ 108,506
 $ 113,932
 $ 116,780
 $ 119,699
 $ 122,692
 $ 124,226
 $ 125,778
 $ 127,351
 $ 128,943
 $ 130,554
 $ 132,186
 $ 133,839
 $ 53,535.43
 $ 13,383.86
 $ 66,919.29

 $ 1,571,081
 $ 1,599,748
 $ 1,629,095
 $ 1,656,297
 $ 1,684,009
 $ 1,712,243
 $ 1,739,476
 $ 1,767,196
 $ 1,795,411
 $ 1,824,132
 $ 1,853,368
 $ 1,883,132
 $ 19,395,040
 $ 7,758,016.00
 $ 2,902,564.07
 $ 8,734,459.92

 Net
 Present Value @ 09/24
 $ 3,359,913.18

 Net
Present Value of Licensed IP @ 9/30/24 $9,735,613.97

 EXHIBIT
B

 TEN-YEAR
PRO-FORMA COST ANALYSIS

 Calculation
of Cost of Domains

 Useful Life of Domain = 10 years

 Cost Basis Approach

 Acquisition Cost
 Initial Development
 Additional Development

 Domain Name
 Sep-24
 Sep-24
 Sep-25

 Polomarsp.com
 $ 1,000.00
 $ 7,500.00
 $ 4,500.00

 SlimRX.com
 $ 1,750.00
 $ 25,000.00
 $ 5,000.00

 Polomarhs.com
 $ 500.00
 $ 17,500.00
 $ 10,000.00

 Polomeds.com
 $ 1,250.00
 $ 20,000.00
 $ 5,000.00

 $ 4,500.00
 $ 70,000.00
 $ 24,500.00

 Total Acquisition & Development
 $ 99,000.00

 Domain Name
 Annual Maintenance

 Jul-25
 Jul-26
 Jul-27
 Jul-28
 Jul-29
 Jul-30
 Jul-31
 Jul-32
 Jul-33
 Jul-34
 Total Maintenance

 Polomarsp.com
 $ 1,250.00
 $ 1,281.25
 $ 1,313.28
 $ 1,346.11
 $ 1,379.77
 $ 1,414.26
 $ 1,449.62
 $ 1,485.86
 $ 1,523.00
 $ 1,561.08

 SlimRX.com
 $ 5,000.00
 $ 5,125.00
 $ 5,253.13
 $ 5,384.45
 $ 5,519.06
 $ 5,657.04
 $ 5,798.47
 $ 5,943.43
 $ 6,092.01
 $ 6,244.31

 Polomarhs.com
 $ 5,000.00
 $ 5,125.00
 $ 5,253.13
 $ 5,384.45
 $ 5,519.06
 $ 5,657.04
 $ 5,798.47
 $ 5,943.43
 $ 6,092.01
 $ 6,244.31

 Polomeds.com
 $ 2,250.00
 $ 2,306.25
 $ 2,363.91
 $ 2,423.00
 $ 2,483.58
 $ 2,545.67
 $ 2,609.31
 $ 2,674.54
 $ 2,741.41
 $ 2,809.94

 $ 13,500.00
 $ 13,837.50
 $ 14,183.44
 $ 14,538.02
 $ 14,901.47
 $ 15,274.01
 $ 15,655.86
 $ 16,047.26
 $ 16,448.44
 $ 16,859.65
 $ 151,245.65

 Total Acquisition, Development and Maintenance
 $ 250,245.65